Intensive lipid lowering reduces mortality following ACS
Clinical QuestionDoes intensive statin therapy reduce mortality in patients with acute coronary syndrome?
Bottom LineIntensive statin therapy following acute coronary syndrome (ACS) reduces cardiovascular and overall mortality. (LOE = 1a)
ReferenceMurphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 2007;100(7):1047-1051. [PMID:17884359]
Study DesignMeta-analysis (randomized controlled trials)
SettingInpatient (any location) with outpatient follow-up
SynopsisThis study pooled results from 2 randomized trials of intensive lipid lowering versus moderate lipid lowering following ACS to attain a large enough sample to detect a mortality difference. The PROVE-IT-TIMI 22 trial enrolled patients within 10 days of ACS and randomized them to receive either atorvastatin 80 mg or pravastatin 40 mg. The A to Z trial enrolled patients within 5 days of ACS and compared simvastatin 40 mg for 1 month followed by simvastatin 80 mg with placebo for 4 months followed by simvastatin 20 mg. Mortality rates for this evaluation were calculated by pooled patient-level data. The 2 trials provided data from a total of 8658 patients. At 4 months and 8 months, the reduction in low-density lipoprotein levels was greatest in the intensive statin group. At 2 years, all-cause mortality was reduced in the intensive statin group compared with the moderate statin group [number needed to treat (NNT) = 77; 95% CI, 46 - 225]. This result was primarily due to a reduction in cardiovascular deaths, which were significantly reduced with intensive therapy (NNT = 112; 61 - 595).
Intensive lipid lowering reduces mortality following ACS is a sample topic from the EE+ POEM Archive.
To view other topics, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.
Barry, Henry, et al., editors. "Intensive Lipid Lowering Reduces Mortality Following ACS." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/426559/all/Intensive_lipid_lowering_reduces_mortality_following_ACS.
Intensive lipid lowering reduces mortality following ACS. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426559/all/Intensive_lipid_lowering_reduces_mortality_following_ACS. Accessed March 31, 2023.
Intensive lipid lowering reduces mortality following ACS. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426559/all/Intensive_lipid_lowering_reduces_mortality_following_ACS
Intensive Lipid Lowering Reduces Mortality Following ACS [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2023 March 31]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426559/all/Intensive_lipid_lowering_reduces_mortality_following_ACS.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Intensive lipid lowering reduces mortality following ACS ID - 426559 ED - Barry,Henry, ED - Ebell,Mark H, ED - Shaughnessy,Allen F, ED - Slawson,David C, BT - EE+ POEM Archive UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/426559/all/Intensive_lipid_lowering_reduces_mortality_following_ACS PB - John Wiley & Sons DB - Evidence Central DP - Unbound Medicine ER -